Q1 EPS Forecast for Boston Scientific Raised by Analyst

Boston Scientific Corporation (NYSE:BSX) – Equities research analysts at Leerink Partnrs upped their Q1 2026 earnings per share estimates for Boston Scientific in a report released on Tuesday, September 9th. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will post earnings of $0.77 per share for the quarter, up from their prior estimate of $0.76. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific’s FY2027 earnings at $3.93 EPS, FY2028 earnings at $4.42 EPS and FY2029 earnings at $4.96 EPS.

Several other brokerages also recently commented on BSX. Robert W. Baird boosted their target price on Boston Scientific from $117.00 to $123.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Morgan Stanley boosted their target price on Boston Scientific from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, May 16th. Wells Fargo & Company boosted their target price on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Raymond James Financial boosted their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 24th. Finally, Leerink Partners began coverage on Boston Scientific in a report on Monday, June 16th. They issued an “outperform” rating and a $118.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific has an average rating of “Buy” and an average price target of $118.04.

Boston Scientific Stock Down 0.7%

Shares of BSX opened at $104.46 on Thursday. The company has a market capitalization of $154.78 billion, a P/E ratio of 62.18, a PEG ratio of 2.53 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific has a one year low of $80.64 and a one year high of $109.50. The business’s 50 day simple moving average is $104.89 and its 200-day simple moving average is $102.24.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company’s quarterly revenue was up 22.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS.

Institutional Trading of Boston Scientific

Institutional investors and hedge funds have recently made changes to their positions in the business. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter valued at $26,000. Sound Income Strategies LLC raised its position in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the last quarter. 1248 Management LLC bought a new stake in shares of Boston Scientific during the 1st quarter valued at $26,000. Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific during the 1st quarter valued at $27,000. Finally, Investment Management Corp VA ADV bought a new stake in shares of Boston Scientific during the 4th quarter valued at $25,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director owned 2,081 shares of the company’s stock, valued at $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 174,214 shares of company stock worth $18,397,457. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.